Regeneron's Eylea grabs key new use in diabetic retinopathy; Merck adds $10B to buyback plan;

@FiercePharma: Why All Those Testosterone Ads Constitute Disease Mongering. Forbes article | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Former Boehringer Ingelheim workers whiplashed by China firm's plans for Virginia API plant. Article | Follow @EricPFierce

@CarlyHFierce: Which diseases are driving drug spending hikes? It's not just hep C. Story | Follow @CarlyHFierce

> Regeneron ($REGN) and Bayer's eye drug Eylea nabbed a new indication in diabetic retinopathy, the most common cause of eye disease in diabetics; the drug's head-to-head rival, Lucentis, won the same approval last month. Release

> Merck & Co. ($MRK) added another $10 billion to its ongoing stock buyback program. Report

> Jordan-based Hikma Pharmaceuticals is planning to meet with investors about a potential dollar-denominated bond issue. Report

> The FDA gave its blessing to an inhaled anthrax treatment, Anthrasil, from Emergent BioSolutions ($EBS), which developed the drug under contract with the U.S. government. Report

> Cosmo Pharmaceuticals, the drugmaker Endo ($ENDP) had planned to buy last year only to abandon the deal, saw 2014 revenue grow by 41.2% to €79 million. Report

Medical Device News

@FierceMedDev: French cancer Dx company born after management buyout at Qiagen unit. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Does the FDA overregulate devices? Experts weigh in. More | Follow @VarunSaxena2

@EmilyWFierce: Cepheid got FDA emergency use authorization for its rapid Ebola test. Release | Follow @EmilyWFierce

> Novartis rides med tech wave with new digital projects. Item

> Pennsylvania surgical tools manufacturing plant scheduled for closure, 250 layoffs planned. Article

Biotech News

@FierceBiotech: Cellectis upscales IPO toward $200M as CAR-T fever continues. Report | Follow @FierceBiotech

@JohnCFierce: ICYMI: Not giving up day job, but interviewing @Asthika from Bloomberg Intelligence on biotech market was fun. Watch | Follow @JohnCFierce

@DamianFierce: Last night's Jeopardy question about CAR-T means this is definitely a bubble, right? | Follow @DamianFierce

> AstraZeneca buys into Harvard's stem cell tech for diabetes R&D. More

> GlaxoSmithKline mounts an open casting call for R&D starlets. Article

> Novartis chief: Sometimes you have to kill your R&D darlings. Story

Biotech Research News

> Concert Pharma spotlights a positive rat study for antiseizure drug. Report

> Duke/NUS team says new combo has promise for mutant-RAS cancers. More

> CMV-based vaccine could help eliminate the threat of Ebola from apes. Story

> Stem cell advance may assist new therapies for anemia, leukemia. Item

> Targeted mitochondrial attack destroys glioma cells in preclinical study. Article

Diagnostics News

> Foundation Medicine reveals C-suite and board metamorphosis. Article

> French cancer Dx company born after management buyout at Qiagen unit. Story

> GE Healthcare's pathology arm to use Omnyx's software for digital analysis of specimens. More

> Dako strikes another cancer companion Dx deal with Amgen. Item

> Roche joins forces with Sigma-Aldrich to distribute biochemical reagents. Article

Pharma Marketing News

> Psoriasis data wars heat up at AAD with Novartis, Boehringer studies. Article

> Were Low-T ads 'disease mongering'? Two experts say yes. Story

> The 2014 DTC ads that made the grade. More

> Pharma's ad spend vaults to $4.5B, with big spender Pfizer leading the way. Article

> Sanofi aims for that sweet smell of success with spring Nasacort campaign. Report

And Finally... Many doctors don't tell their patients when they diagnose Alzheimer's. Report

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.